About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals news and updates
Amylyx Pharmaceuticals hired Gina M. Mazzariello as Chief Legal Officer on Feb 22nd 22'.
Amylyx Pharmaceuticals, Inc., (Nasdaq: AMLX) (“Amylyx” or the “Company”), today announced the appointment of Gina M. Mazzariello as Amylyx’ Chief Legal Officer (CLO) and General Counsel, where she will oversee all legal and compliance matters for the Company.
Jan 1, 2022 | acrofan.comAmylyx Pharmaceutical Corp. launches AMX0035 should the CHMP review result
“Amylyx Pharmaceutical Corp. is building out its European team to be prepared to launch AMX0035 should the CHMP review result in a positive opinion, as Amylyx Pharmaceutical Corp. know people with ALS and their families have no time to wait.”
Jan 1, 2022 | amylyx.comAmylyx Pharmaceutical Corp. is developing novel therapeutic for amyotrophic lateral sclerosis
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Jan 1, 2022 | businesswire.comAmylyx Pharmaceutical Corp. launched Expanded Access Program for AMX0035 on Mar 18th 22'.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) announced today the launch of an Expanded Access Program (EAP) for AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) in the U.S. for people living with amyotrophic lateral sclerosis (ALS) that meet program eligibility criteria.
Jan 1, 2022 | galvnews.comAmylyx Pharmaceutical Corp. has issues with securities fraud or other unlawful business practices
The investigation concerns whether Amylyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | benzinga.comAmylyx Pharmaceutical Corp. has issues with violated federal securities laws
The investigation concerns whether Amylyx and certain of its officers and/or directors have violated federal securities laws.
Jan 1, 2022 | benzinga.comAmylyx Pharmaceutical Corp. is developing novel therapeutic for amyotrophic lateral sclerosis
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Jan 1, 2022 | bakersfield.comAmylyx Pharmaceutical Corp. will develop AMX0035 on Sep 1st 22'.
Amylyx also is developing a novel ALS therapy, AMX0035, that is under review by the U.S. Food and Drug Administration, with a decision expected in late September.
Jan 1, 2022 | alsnewstoday.comAmylyx Pharmaceutical Corp. receives financing of $3M in grant
Some of that funding from the Ice Bucket Challenge went to grants, and Amylyx received a $3 million grant.
Sep 28, 2022 | bostonherald.comAmylyx Pharmaceutical Corp. is developing novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Nov 25, 2022 | investorsobserver.com